NKGen Biotech obtains additional $251K loan, secured note now $26.8M

NKGen Biotech, Inc.

Entered third amendment to secured promissory note with AlpineBrook Capital for additional $251,000 loan.
Total principal amount of secured promissory note increased to $26,758,106.
Interest on the new loan begins accruing from January 30, 2026, the funding date.
Loan is part of a series of amendments; prior principal was $26,507,106 after second amendment.

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

NKGen Biotech, Inc. incurred loan of $251,000 with AlpineBrook Capital GP I Limited.

Instrument: loan
Principal: $251,000
Counterparty: AlpineBrook Capital GP I Limited
Event: incurrence

Exact text from the filing

The Alpine Third Amendment provides an additional $251,000 of funding to the Borrowers (the "Fourth Additional New Loan").

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NKGen Biotech, Inc. amended Alpine Third Amendment with AlpineBrook Capital GP I Limited valued at $251,000 (effective 2026-01-30).

Action: amendment
Agreement: credit facility
Counterparty: AlpineBrook Capital GP I Limited
Value: $251,000
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, NKGen Biotech, Inc. (the “Company”) and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a third amendment (the “Alpine Third Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001213900-26-012879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.